Login to Your Account

Symdeko cleared, triplet ahead?

The French disconnection: Vertex's CF victory in U.S. shadowed by payer trouble

By Randy Osborne
Staff Writer

Wednesday, February 14, 2018

Pundits had more to debate than the U.S. reimbursement prospects for Vertex Pharmaceuticals Inc.'s cystic fibrosis (CF) drug Symdeko (tezacaftor/ivacaftor and ivacaftor), cleared by regulators just as the company halted phase III trials in France with a triple-combo CF prospect because a deal couldn't be reached there on reimbursement for another Vertex therapy, Orkambi (lumacaftor/ivacaftor).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription